A win-odds analysis is a statistical method used to analyze clinical trial data to evaluate the effectiveness of treatments. It provides a novel way to measure treatment effect by comparing the number ...
Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data ...
Servier today announced that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2025, in Orlando, Florida. Presentations will ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants ...
Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...
Helius Medical Technologies ( (HSDT) ) has provided an update.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...
The trial was halted due to inadequate efficacy, Jay Bradner, M.D., Amgen’s executive vice president of R&D, said during a Nov. 4 call with investors, after an ad hoc analysis requested by an internal ...
A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...
Allogene Therapeutics, Inc. downgraded to Hold after ALPHA3 trial setbacks. Review updated pipeline prospects and risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback